ClinicalTrials.gg
Not yet recruitingNCT07653464Updated Oct 15, 2026

Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity

An Early Phase 1 interventional study of human insulin in Obesity (BMI>30) and Insulin Resistance, sponsored by University of Missouri-Columbia. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Missouri-Columbia · Early Phase 1, Interventional, and Basic science

How we know

Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Obesity by University of Missouri-Columbia — 8 open to participants now, 9 under way, none of them phase 3. Obesity · University of Missouri-Columbia.

Planned enrollment
9th of 29
64 · median 40
Started
2026
with 2 others
Phase 1
6 of 34
3 open now
Registered
33rd of 34
by date

Among the 34 studies in Obesity by University of Missouri-Columbia, this one is the 9th largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 1, and was the 33rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 34 studies in Obesity by University of Missouri-Columbia are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Obesity by University of Missouri-Columbia, or all of them as a file.
02

Study summary

Determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.

03

Conditions studied

  • Obesity (BMI>30)
  • Insulin Resistance
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years of age

Individuals with obesity and comorbid IR

  • 30-45 kg/m2
  • Waist circumference ≥102 cm (men) or ≥88 cm (women)
  • HOMA-IR ≥2.5

Healthy normal weight adults

  • BMI 18-25 kg/m2
  • Waist circumference \<94 cm (men) and \<80 cm (women)
  • HOMA-IR \<2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding
  • Unable to provide consent
  • Diabetes or polycystic ovarian syndrome
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
  • Nerve/neurologic disease
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Current smoking, tobacco, nicotine use
  • Use of pharmacological therapy for weight loss
  • Body weight change >10% within the last 6 months
  • Adherence to >150 min/week of moderate-to-vigorous physical activity/exercise
  • Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months
  • Claustrophobia
  • Non-MRI compatible metal implants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Insulin (Doppler)

    Human insulin (160 IU) will be administered using an intra-nasal device

    Drug: human insulin

  • Experimental
    Insulin (MRI)

    Human insulin (160 IU) will be administered using an intra-nasal device.

    Drug: human insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of muscle sympathetic nerve activity (MSNA)

    MSNA burst incidence (bursts/100 heart beats)

    Time frame: Change from baseline at minute 30

  2. Amount of cerebral blood flow

    Measured with arterial spin labeling (mL/100 g/min)

    Time frame: Change from baseline at minute 30

  3. Amount of leg blood flow

    Measured with Doppler ultrasound (mL/min)

    Time frame: Change from baseline at minute 30

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2031, 54 months later.

Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's planned 54 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07653464
Responsible party
Jacqueline K Limberg, PhD (Associate Professor, University of Missouri-Columbia) — Principal investigator
First posted
Jun 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Jacqueline Limberg
Contact
limberglab@missouri.edu
573-882-2544

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion